Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewPSB 0777 ammonium salt
说明： Potent adenosine A2A agonist
化学名： 4-[2-[(6-Amino-9-b-D-ribofuranosyl-9H-purin-2-yl)thio]ethyl]benzenesulfonic acid ammonium salt
纯度： ≥97% (HPLC)
生物活性 for PSB 0777 ammonium salt
PSB 0777 ammonium salt is a potent adenosine A2A receptor full agonist (Ki = 44.4 nM for rat brain striatal A2A receptors). Exhibits subtype selectivity for A2A receptors over A1, A2B and A3 receptors (Ki ≥ 10 000 nM for rat A1, human A2B and human A3 receptors). Potentiates acetylcholine-induced contractions in ex vivo rat ileum/jejunum segments.
化合物库 for PSB 0777 ammonium salt
PSB 0777 ammonium salt is also offered as part of the Tocriscreen 2.0 Max. 了解 Tocris 化合物库的更多信息。
技术数据 for PSB 0777 ammonium salt
| 分子量 | 500.55 |
| 公式 | C18H20N5O7S2.NH4 |
| 储存 | Store at RT |
| 纯度 | ≥97% (HPLC) |
| CAS Number | 2122196-16-9 |
| PubChem ID | 90488932 |
| InChI Key | AYQGFWKUGKSGCZ-VSAOVUCUSA-N |
| Smiles | NC1=C3C(N([C@@H]4O[C@H](CO)[C@@H](O)[C@@H]4O)C=N3)=NC(SCCC2=CC=C(S(=O)(O)=O)C=C2)=N1.N |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶解性数据 for PSB 0777 ammonium salt
| 溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
|---|---|---|---|
| 溶解性 | |||
| water | 50.05 | 100 | |
| DMSO | 50.05 | 100 |
制备储备液 for PSB 0777 ammonium salt
以下数据基于产品分子量 500.55。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| 浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 2 mL | 9.99 mL | 19.98 mL |
| 5 mM | 0.4 mL | 2 mL | 4 mL |
| 10 mM | 0.2 mL | 1 mL | 2 mL |
| 50 mM | 0.04 mL | 0.2 mL | 0.4 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
产品说明书 for PSB 0777 ammonium salt
参考文献 for PSB 0777 ammonium salt
参考文献是支持产品生物活性的出版物。
El-Tayeb et al (2012) Development of polar adenosine A2A receptor agonists for inflammatory bowel disease: synergism with A2B antagonists. ACS Med.Chem.Lett. 2 890 PMID: 24900277
If you know of a relevant reference for PSB 0777 ammonium salt, please let us know.
按产品操作查看相关产品
关键词: PSB 0777 ammonium salt, PSB 0777 ammonium salt supplier, Adenosine, A2A, receptors, agonists, potent, subtypes, selective, PSB0777, ammonium, salt, Receptors, 4334, Tocris Bioscience
2 篇 PSB 0777 ammonium salt 的引用文献
引用文献是使用了 Tocris 产品的出版物。 PSB 0777 ammonium salt 的部分引用包括：
Gemma et al (2020) Experimental and computational analysis of biased agonism on full-length and a C-terminally truncated adenosine A2A receptor. Comput Struct Biotechnol J 18 2723-2732 PMID: 33101610
Cezary et al (2020) Adenosine Receptor Agonists Increase the Inhibition of Platelet Function by P2Y12 Antagonists in a cAMP- and Calcium-Dependent Manner. Pharmaceuticals (Basel) 13 PMID: 32752089
您是否知道使用了 Tocris PSB 0777 ammonium salt 的优秀论文？ 请告知我们.
PSB 0777 ammonium salt 的评论
目前没有该产品的评论。 Be the first to review PSB 0777 ammonium salt and earn rewards!
Have you used PSB 0777 ammonium salt?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
该领域的文献
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.